Maintenance of Th1 Hepatitis C Virus (HCV)-specific Responses in Individuals with Acute HCV Who Achieve Sustained Virological Clearance After Treatment
Overview
Authors
Affiliations
Background And Aim: T-cell responses against hepatitis C are believed to be critical in achieving both natural and treatment-induced clearance. However, rapid clearance of antigen with early treatment of primary infection may result in reduced or poorly sustained cellular immunity. This study longitudinally examined Th1 and Th2 hepatitis C virus (HCV)-specific cytokine production and T-cell effector function from subjects enrolled in the Australian Trial in Acute Hepatitis C comparing three groups: treatment-induced clearance (sustained virological response [SVR]), treatment non-response, and untreated spontaneous clearance.
Methods: HCV-specific T-cell responses were characterized by HCV peptide ELISpot, in vitro cytokine production, and T-cell flow cytometry assays.
Results: Treated subjects with a sustained virological response (SVR) displayed a better maintenance of HCV-specific Th1 responses compared to treatment non-responders (higher interferon [IFN]-γ and interleukin (IL)-2 magnitude at week 24, broader IFN-γ responses at weeks 24 and 48, P < 0.05) and significantly increased IFN-γ responses between screening and week 48 (magnitude P = 0.026, breadth P = 0.009). Treatment-induced viral clearance was also associated with a trend toward decreased IL-10 responses (screening to week 48, P = 0.070), higher expression of CD45RO (P = 0.042) and CD38 (P = 0.088) on CD4+ T cells, and higher IFN-γR expression (CD56+ IFN-γR+ P = 0.033) compared to treatment non-responders. Untreated subjects with viral clearance also displayed high magnitude and broad HCV-specific IFN-γ and IL-2 responses early in infection; however, IFN-γ responses were not as well maintained compared to treated subjects with a SVR (week 48 magnitude, breadth P = 0.064).
Conclusion: Treatment-induced viral clearance of recent HCV infection is associated with maintenance of HCV-specific Th1 responses.
Hammel A, Cucos L, Caras I, Ionescu I, tucureanu C, Tofan V Proc Natl Acad Sci U S A. 2024; 121(24):e2400145121.
PMID: 38833465 PMC: 11181018. DOI: 10.1073/pnas.2400145121.
Jacobson J, Zahrieh D, Strand C, Cruz-Correa M, Pungpapong S, Roberts L Cancer Prev Res (Phila). 2022; 16(3):163-173.
PMID: 36534786 PMC: 9992130. DOI: 10.1158/1940-6207.CAPR-22-0217.
Marin M, Sliepen K, Garcia-Arriaza J, Koekkoek S, Perez P, Sorzano C Vaccines (Basel). 2020; 8(3).
PMID: 32764419 PMC: 7563715. DOI: 10.3390/vaccines8030440.
Hope J, Stairiker C, Bae E, Otero D, Bradley L Front Immunol. 2019; 10:1595.
PMID: 31379821 PMC: 6650570. DOI: 10.3389/fimmu.2019.01595.
Role of T-Helper 9 Cells in Chronic Hepatitis C-Infected Patients.
Ali M, El-Badawy O, Afifi N, Sharaf Eldin A, Hassan E, Halby H Viruses. 2018; 10(7).
PMID: 29937515 PMC: 6071239. DOI: 10.3390/v10070341.